EGFR and non-small cell lung carcinoma: While some may criticize the study population for being molecularly unselected patients receiving initial EGFR kinase inhibitor therapy, rather than EGFR mutant NSCLC patients with acquired kinase inhibitor resistance, we believed the population to be appropriate for this dose escalation study.